Research programme: gene therapies - bluebird bio
Latest Information Update: 18 Aug 2021
At a glance
- Originator bluebird bio
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inborn genetic disorders
Most Recent Events
- 04 Aug 2021 Gene therapies are available for licensing as of 04 Aug 2021. https://www.bluebirdbio.com/about-us/collaborations
- 04 Aug 2021 Preclinical trials in Inborn genetic disorders in USA (Parenteral) (bluebird-bio pipeline, August 2021)